Since NRAS mutations cause aberrant activation of the mitogen-activated protein kinase pathway in melanoma [12], there is considerable interest in the development of mitogen-activated extracellular signal-related kinase (MEK) inhibitors as a novel treatment strategy that could improve the clinical outcomes of these patients. The gene discussed is NRAS; the disease is melanoma.